| Xiidra (U.S.N.L.M.) | |
|---|---|
| Dosing | One drop BID |
| Chem Specs | lifitegrast ophthalmic solution 5% |
| Quantities | Cartons of 60 single-use containers (each carton has 12 pouches, with 5 single-use containers) |
| Cost | $685.86 / carton (60) |
| Class | LFA-1 antagonist |
| Action | Binds to leukocyte cell surface protein (LFA-1) reducing T-cell activation and inflammatory cytokine secretion. The exact mechanism of action of lifitegrast in dry eye disease is not known. |
| Usage | Indicated for the treatment of the signs and symptoms of dry eye disease. |
| 5 - 25% of patients experience irritation, dysgeusia and reduced VA. | |
| Contraindications | None |
| Pediatric use | Safety and efficacy not established in pediatric patients below the age of 17. |
| Pregnancy | Teratogenic when administered to rats at 400x the normal human dose. |
| Remove contact lenses prior to use; reinsert 15 minutes following administration. |